![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy and Safety of B/F/TAF in Hispanic/Latine Adults With HIV-1 Initiating First-Line Therapy: 5-Year Follow-up From Two Phase 3 Studies
|
|
|
AIDS 2024 July 20-26 Munich
Claudia Martorell1, Olayemi Osiyemi2, Mezgebe Berhe3, Lizette Santiago4, Christopher Rosero5, Fang Fang5, Nathan Unger5, Jason T Hindman5, Moti Ramgopal6
1The Research Institute, Springfield, MA, USA; 2Triple O Research Institute, West Palm Beach, FL, USA; 3North Texas Infectious Diseases Consultants, Dallas, TX, USA; 4HOPE Clinical Research, San Juan, Puerto Rico; 5Gilead Sciences, Inc., Foster City, CA, USA; 6Midway Immunology and Research Center, Fort Pierce, FL, USA
![0731241](../images/073124/073124-6/0731241.gif)
![0731242](../images/073124/073124-6/0731242.gif)
![0731243](../images/073124/073124-6/0731243.gif)
SEE BELOW for Supplemtary materials: participants regional distribution, etc.
![0731244](../images/073124/073124-6/0731244.gif)
![0731245](../images/073124/073124-6/0731245.gif)
SEE BELOW for Supplemtary materials: participants regional distribution, metabolic, renal outcomes
![0731246](../images/073124/073124-6/0731246.gif)
![0731247](../images/073124/073124-6/0731247.gif)
![0731248](../images/073124/073124-6/0731248.gif)
![0731249](../images/073124/073124-6/0731249.gif)
![07312410](../images/073124/073124-6/07312410.gif)
![07312411](../images/073124/073124-6/07312411.gif)
![07312412](../images/073124/073124-6/07312412.gif)
![07312413](../images/073124/073124-6/07312413.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|